{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:57Z","timestamp":1791684597053,"version":"4.3.4"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is frequently complicated with rapidly progressive-interstitial lung disease (RP-ILD). The prognosis of MDA5-DM with RP-ILD is mostly poor despite intensive treatment with a combination of high-dose glucocorticoids and single conventional immunosuppressants. It was reported that the triple therapy (high-dose glucocorticoids, cyclophosphamide and tacrolimus) was more effective than a combination of high-dose glucocorticoids and stepwise addition of immunosuppressants. In addition, the efficacy of tofacitinib 10\u2009mg\/day for MDA5-DM with RP-ILD refractory to the triple therapy was suggested. However, the effect of those therapies was evaluated only in comparison to the historical control. Moreover, more importantly, there are still refractory patients even if treated with those therapies. In this case series, we report six MDA5-DM cases with RP-ILD in which the dose of tofacitinib was increased from 10 mg to 20 mg\/day due to poor response to the triple therapy, followed by tofacitinib 10\u2009mg\/day. Four of six patients improved after dose escalation of tofacitinib, while two non-responders died. All six patients developed at least one infection including five cases of cytomegalovirus reactivation, one pulmonary aspergillosis, one herpes zoster and one herpes simplex keratitis. These cases suggest that the dose escalation of tofacitinib can be an option for MDA5-DM patients refractory to 10\u2009mg\/day of tofacitinib and other immunosuppressants although the risk of infection is a concern. The risk\u2013benefit balance of the dose escalation of tofacitinib should be carefully assessed in each case.<\/jats:p>","DOI":"10.1136\/rmdopen-2022-002795","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T10:50:47Z","timestamp":1672656647000},"page":"e002795","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-336X","authenticated-orcid":false,"given":"Tomoaki","family":"Ida","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunjiro","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-3518","authenticated-orcid":false,"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-2970","authenticated-orcid":false,"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-9381","authenticated-orcid":false,"given":"Hiroshi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"2025090312030478000_9.1.e002795.1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with Anti-MDA5 antibodies: Bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"2025090312030478000_9.1.e002795.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21985"},{"key":"2025090312030478000_9.1.e002795.3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312030478000_9.1.e002795.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009727"},{"key":"2025090312030478000_9.1.e002795.5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312030478000_9.1.e002795.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"2025090312030478000_9.1.e002795.7","doi-asserted-by":"crossref","unstructured":"Kato M , Ikeda K , Kageyama T , et al . Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with Anti-MDA5 antibody-positive dermatomyositis. J Clin Rheumatol 2019.doi:10.1097\/RHU.0000000000000984","DOI":"10.1097\/RHU.0000000000000984"},{"key":"2025090312030478000_9.1.e002795.8","article-title":"Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically Amyopathic dermatomyositis","author":"Hama","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025090312030478000_9.1.e002795.9","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.1097\/RHU.0000000000001645","article-title":"A case of refractory interstitial lung disease in anti-MDA5-positive dermatomyositis that improved after switching to tofacitinib","volume":"27","author":"Hosokawa","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2025090312030478000_9.1.e002795.10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312030478000_9.1.e002795.11","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199911000-00006"},{"key":"2025090312030478000_9.1.e002795.12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025090312030478000_9.1.e002795.13","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-022-00693-0","article-title":"Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib","volume":"27","author":"Luo","year":"2022","journal-title":"Eur J Med Res"},{"key":"2025090312030478000_9.1.e002795.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"2025090312030478000_9.1.e002795.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2025090312030478000_9.1.e002795.16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025090312030478000_9.1.e002795.17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0\u00a0years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312030478000_9.1.e002795.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090312030478000_9.1.e002795.19","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled oral surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090312030478000_9.1.e002795.20","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24726","article-title":"Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease","volume":"36","author":"Li","year":"2022","journal-title":"J Clin Lab Anal"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:03:23Z","timestamp":1756926203000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,2]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/rmdopen-2022-002795"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002795","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}